Kategorie: News

GBT Pharma is to build new business affiliations for Ceuta International Alliance across the South, Central and Latin American markets.

Specialists in driving international market entry for consumer healthcare companies, GBT Pharma has been appointed to identify and secure key health and beauty distributor partnerships within these territories.

Key markets will include Brazil, Columbia, Peru, Chile, Panama, Costa Rica and Ecuador.

Peter Burrows, International Business Development Director at Ceuta Healthcare comments: “Consumer healthcare products sit within a complex and heavily regulated sector.

«GBT Pharma’s proven track record in managing and developing international market opportunities within this field speaks for itself.

«We are delighted to be working with them as our chosen partner to identify the right calibre of partners to represent our unique International Alliance to drive international growth within these regions.”

GBT Pharma founder Gian Trepp comments: “This is an exciting trade mission for GBT Pharma. We will be utilising our experience and strong networks within these markets to align relevant distribution partners to represent the Ceuta International Alliance across this vast territory.

“We look forward to forging fruitful and long lasting new trade relationships for Ceuta Healthcare in the coming months,” added Gian.

For further information on the Ceuta Alliance network, please visit: www.ceutaalliance.com

For further information on GBT Pharma, please visit: www.gbtpharma.com

One of GBT Pharma’s latest projects has seen the team busy re-establishing a presence for Similasan’s eye care range in the Netherlands.

Partnering with the newly founded Dutch subsidiary – Similasan Nederland BV – GBT Pharma has been intensively devising a re-launch programme for this leading brand of allergy eye care products.

Up until 2012, Similasan was the market leading homeopathic eye care brand in the Netherlands. The forthcoming re-launch follows a year long voluntary absence from the Dutch market for the brand.

During this time, GBT Pharma worked closely with Similasan advising on a revised regulatory and customer-facing strategy to support the brand following regulatory changes implemented by the Dutch Ministry of Health in September 2012.

“This is an exciting time to be re-launching Similasan,” comments Gian Trepp, GBT Pharma founder. “Not only is the Dutch market buoyant, after adapting our strategy we will be re-launching four Similasan products as medical devices from June 2014.

“The launch of Similasan’s Dutch branch will support a specific focus on re-establishing this popular brand within key retailers, the independents, drugstores and pharmacies ultimately increasing Similasan’s future role and participation in the Dutch self-care market.

“As well as re-building the Similasan brand in the Netherlands we will be offering in-licensing and product development opportunities to fulfill emerging customer needs in the market,” adds Gian.

Parties interested in listing the Similasan eye care range, or to discuss in-licensing opportunities are invited to contact us: http://www.gbtpharma.com/contact-us

GBT Pharma are now members of the Europharm Association, the industry network for SME European pharmaceutical companies.

With a wide client base across Europe, GBT Pharma is the chosen partner to drive international market success for a variety of consumer healthcare brands.

This latest move will ensure the GBT Pharma healthcare company is even better placed to maintain its competitive edge in the consumer health product market.

“We are delighted to now be a part of the Europharm network,” comments GBT Pharma founder Gian Trepp.

“Consumer healthcare products are a complex sector and Europharm provides a most valuable resource and support for SME pharma companies.

“We very much look forward to building links with potential partners and promoting the sharing of mutual knowledge as part of the Europharm network,” adds Gian.